An observational study in Portal Hypertension, Gastroesophageal Varices Hemorrhage and Gastric Varices, sponsored by Shanghai Zhongshan Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.
Sponsored by Shanghai Zhongshan Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Esophageal and Gastric Varices by Shanghai Zhongshan Hospital — 2 open to participants now, 2 under way, none of them phase 3. Esophageal and Gastric Varices · Shanghai Zhongshan Hospital.
Among the 13 studies in Esophageal and Gastric Varices by Shanghai Zhongshan Hospital, this one is the only one that started in 2026, is one of 4 observational ones, and was the 13th registered.
150 studies on the registry are indexed under Esophageal and Gastric Varices; 39 are open to participants now.
Browse Esophageal and Gastric Varices studies →2 of the 13 studies in Esophageal and Gastric Varices by Shanghai Zhongshan Hospital are open now, in 1 country. Recruiting first, the newest first:
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 20 Esophageal and Gastric Varices studies recruiting now, 13 (65%) set no upper age limit and 1 (5%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,066 is above the median of 130 across 44 observational studies indexed under Esophageal and Gastric Varices.
Median enrollment 120 across the 9 interventional studies, 1,385 across the 4 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai Zhongshan Hospital is the lead sponsor of 654 studies on the registry; 293 are open to participants now.
1 of the studies in Esophageal and Gastric Varices by Shanghai Zhongshan Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07502729Shanghai Zhongshan HospitalOptimizing Endoscopic and Interventional Treatment for Portal Hypertensive Bleeding | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Esophageal and Gastric Varices by Shanghai Zhongshan Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the impact of high-risk factors-such as elevated portal venous pressure, concurrent large extra-luminal vessels, portal vein thrombosis, and prominent portosystemic shunts-on the efficacy of endoscopic therapy. By comparing with interventional treatment, the goal is to optimize the clinical management protocol for esophageal and gastric varices, enhance the therapeutic outcomes of portal hypertension-related esophageal and gastric varices, and improve patient prognosis.
150 studies on the registry are indexed under Esophageal and Gastric Varices; 39 are open to participants now.
This study's planned enrollment of 1,066 is above the median of 130 across 44 observational studies indexed under Esophageal and Gastric Varices.
Browse Esophageal and Gastric Varices studies →Shanghai Zhongshan Hospital is the lead sponsor of 654 studies on the registry; 293 are open to participants now.
Compared within Esophageal and Gastric Varices, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Portal. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Enrolled were patients who presented to Zhongshan Hospital, Fudan University and other study centers due to esophagogastric variceal bleeding secondary to portal hypertension between December 2025 and December 2026.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The patient underwent Transjugular Intrahepatic Portosystemic Shunt (TIPS) after admission
The patient only received endoscopic treatment after admission.
1-year gastrointestinal rebleeding rate
Time from initial variceal bleeding treated with endoscopy or TIPS to recurrent variceal rupture and bleeding due to portal hypertension (at least 120 hours)
Time frame: 1 year after the treatment.
2-month and 6-month gastrointestinal rebleeding rates
Time from initial variceal bleeding treated with endoscopy or TIPS to recurrent variceal rupture and bleeding due to portal hypertension (at least 120 hours)
Time frame: 2 months and 6 months after the treatment
Indicators in the Child-Pugh classification include the progression of ascites and changes in bilirubin levels.
Depth of abdominal fluid dark area detected by abdominal ultrasound; changes in serum bilirubin levels in liver function tests.
Time frame: 1, 2, 6, and 12 months after the treatment.
Changes of portal vein thrombosis
Evaluate the occurrence, recanalization, and other changes in thrombosis every 6 months using portal CTA and ultrasound.
Time frame: 6 and 12 months after the treatment.
Liver cancer
Hepatocellular carcinoma or cholangiocarcinoma
Time frame: Up to 12 months after the treatment.
Liver transplantation
Based on comprehensive clinical evaluation, liver transplantation is required.
Time frame: Up to 12 months after the treatment.
Variceal bleeding-related mortality
During the follow-up period, deaths caused by variceal rupture and bleeding that occurred within 6 weeks after the bleeding episode and were clearly related to the bleeding, including hemorrhagic shock and multiple organ failure.
Time frame: Up to 12 months after the treatment.
Liver-related mortality
Deaths resulting from variceal rupture and bleeding, liver failure, hepatic encephalopathy, infection, hepatorenal syndrome, etc., excluding deaths due to extrahepatic causes, including: accidental death, cardiovascular events, and deaths caused by other systemic cancers.
Time frame: Up to 12 months after the treatment.
No study locations are listed for this record.
Plan to share: Yes
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Dec 2026, 9 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Esophageal and Gastric Varices →